The role of cytokines in non-alcoholic steatohepatitis. A systematic review

Journal of Gastrointestinal and Liver Diseases

Volumn 15, Issue 4, 2006, Pages 363-373

  Copaci, Ionel ^a   Micu, Laurentiu ^a   Voiculescu, Mihai ^a  

^a FUNDENI CLINICAL INSTITUTE   (Romania)

Author keywords

Cytokines; Liver fibrosis; Metabolic syndrome; NASH; TNF

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACYLATION STIMULATING PROTEIN; ADIPONECTIN; CYTOKINE; GAMMA INTERFERON; GLUCOSE TRANSPORTER 4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; LEPTIN RECEPTOR; METFORMIN; NEUROTRANSMITTER; NORADRENALIN; PENTOXIFYLLINE; RESISTIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ACYLATION; ADIPOCYTE; APOPTOSIS; DISEASE COURSE; HUMAN; INSULIN RESISTANCE; LIVER FIBROSIS; METABOLIC SYNDROME X; NATURAL KILLER CELL; NEUROTRANSMISSION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOGENESIS; PREVALENCE; PROTEIN FUNCTION; REVIEW; SEX RATIO; TH1 CELL; TH2 CELL;

ADIPOCYTES; ADIPOKINES; ANIMALS; CYTOKINES; DISEASE PROGRESSION; FATTY LIVER; HUMANS; INFLAMMATION MEDIATORS; LIVER; LIVER CIRRHOSIS; METABOLIC SYNDROME X;

EID: 33846322877     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Avogaro P, Crepaldi G, Enzi G, Tiengo A. Associazione di iperlipemia, diabete mellito e obesita di medio grado. Acta Diabetol Lat 1967; 4; 572-590
2. Reaven GM. (Banting Lecture 1988) Role of insulin resistance in human disease. Diabetes 1989; 37: 1595-1607
3. WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. World Health Organization, WHO/NCD/NCS/99.2, 1999
4. Haffner SM, Valdez RA, Hazuda H et al. Prospective analysis of the insulin-resistance syndrome. Diabetes 1992; 41: 715-722
5. Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-923
6. Rajala MW, Scherer PE. Minireview: The adipocyte - at the crossroads of energy homeostasis, inflammation and atherosclerosis. Endocrinology 2003; 144: 3765-3773
7. Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation and atherogenesis. Endocrinology 2003; 144: 2195-2200
8. Chalasani N, Deeg MA, Persohn S et al. Metabolic and anthropometric evaluation of insulin resistance in nondiabetic patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003; 98: 1849-1855
9. Hirosumi J, Tuncman G, Chang L et al. A central role for JNK in obesity and insulin resistance. Nature 2002; 420: 333-336
10. Bluher M, Michael MD, Peroni OD et al Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev Cell 2002; 3: 25-28
11. Friedman JM. The function of leptin in nutrition, weight and physiology. Nutr Rev 2002; 60: S1-S14
12. Niswender KD, Schwartz MW. Insulin and leptin revisited: adiposity signals with overlapping physiological and intracellular signaling capabilities. Front Neuroendocrinol 2003; 24: 1-10
13. Minokoshi Y, Kim YB, Peroni OD et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002; 415: 339-343
14. Hotta K, Funahashi T, Bodkin NL et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001; 50: 1126-1133
15. Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83
16. Fernandez-Real JM, Lopez-Bermejo A, Casamitjana R et al. Novel interactions of adiponectin with the endocrine system and inflammatory parameters. J Clin Endocrinol Metab 2003; 88: 2714-2718
17. Kern PA, Di Gregorio GB, Lu T et al. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 2003; 52: 1779-1785
18. Spranger J, Kroke A, Mohlig M et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003; 361: 226-228
19. Kissebah AH, Sonnenberg G, Myklebust J et al Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc Natl Acad Sci USA 2000; 97: 14478-14483
20. Vionnet N, Hani El H, Dupont S et al. Genomewide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24. Am J Hum Genet 2000; 67: 1470-1480
21. Kaser S, Moschen A, Cayon A, Kaser A et al. Adiponectin and its receptors in nonalcoholic steatohepatitis. Gut 2005; 54: 117-121
22. Musso G, Gambino R, Biroli G, Carello M et al. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic β-cell dysfunction in nondiabetic nonobese patients with non-alcoholic steatohepatitis. Am J Gastroenterol 2005;100:1-9
23. Steppan CM, Bailey ST, Bhat S et al.The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312
24. Rajala MW, Obici S, Scherer PE, Rossetti L. Adipose-derived resistin and gut-derived resistin-like molecule-β selectively impair insulin action on glucose production. J Clin Invest 2003; 111: 225-230
25. Sniderman AD, Maslowska M, Cianflone K. Of mice and men (and women) and the acylation-stimulating protein pathway. Curr Opin Lipidol 2000; 11: 291-296
26. Xia Z, Sniderman AD, Cianflone K. Acylation-stimulating protein (ASP) deficiency induces obesity resistance and increased energy expenditure in ob/ob mice. J Biol Chem 2002; 277: 45874-45879
27. Faraj M, Havel PJ, Phelis S et al. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2003; 88: 1594-1602
28. Yesilova Z, Ozata M, Oktenli C, Bagci S et al. Increased acylation stimulating protein concentrations in nonalcoholic fatty liver disease are associated with insulin resistance. Am J Gastroenterol 2005; 100: 842-849
29. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest 1994; 94: 1543-1549
30. Lin Y, Rajala MW, Berger JP et al. Hyperglycemia-induced production of acute phase reactants in adipose tissue. J Biol Chem 2001; 276: 42077-42083
31. Yang J, Goetz D, Li Jy et al. An iron delivery pathway mediated by a lipocalin. Mol Cell 2002; 10: 1045-1056
32. Hirokawa J, Sakaue S, Tagami S et al. Identification of macrophage migration inhibitory factor in adipose tissue and its induction by tumor necrosis factor- alpha. Biochem Biophys Res Commun 1997; 235: 94-98
33. Juge-Aubry CE, Somm E, Giusti V et al. Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. Diabetes 2003; 52: 1104-1110
34. Lin Y, Lee H, Berg AH et al. The hipopolysactharide-activated toll-like receptor TLR-4 induces synthesis of the closely related receptor TLR-2 in adipocytes. J Biol Chem 2000; 275: 24255-24263
35. The Examination Committee of Criteria for "Obesity Disease" in Japan, Japan Society for the Study of Obesity. New criteria for "obesity disease" in Japan. Circ J 2002; 66: 987-992
36. Matsuzawa Y. Pathophysiology and molecular mechanism of visceral fat syndrome: the Japanese experience. Diabetes Metab Rev 1997; 13: 1-13
37. Bird GL, Sheron N, Goka AK et al. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med 1990; 112: 917-920
38. McClain CJ, Cohen DA Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology 1989; 9: 349-351
39. Iimuro Y, Galluci RM, Luster MI et al. Antibodies to tumor necrosis factor-α attenuates hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology 1997; 26: 1530-1537
40. Katsuki A, Sumida Y, Urakawa H et al. Increased visceral fat and serum levels of triglyceride are associated with insulin resistance in Japanese metabolically obese, normal weight subjects with normal glucose tolerance. Diabetes Care 2003; 26: 2341-2344
41. Lebovitz HE. The relationship of obesity to the metabolic syndrome. Int J Clin Pract Suppl 2003; 134: 18-27
42. Kern PA, Saghizaheh M, Ong JM. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995; 95: 2111-2119
43. Crespo J, Cayon A, Fernandez-Gil P et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in non-alcoholic steatohepatitis patients. Hepatology 2001; 34: 1158-1163
44. Valenti L, Fracanzani AL, Dongiovanni P. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in non-alcoholic fatty liver disease. Gastroenterology 2002; 122:274-280
45. Wigg AJ, Roberts-Thomson IC, Dymock RB. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001; 48 : 206-211
46. Zhang Y, Proenca R, Maffei M. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-432
47. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: implications for pathogenesis of steatohepatitis. Proc Natl Acad Sci USA 1997; 94: 2557-2562
48. Sanna V, Di Giacomo A, La Cava A. Leptin surge precedes onset of autoimmune encephalomyelitis and correlates with development of pathogenic T cell responses. J Clin Invest 2003; 111: 241-250
49. Guebre-Xabier M, Yang SJ, Lin HZ. Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: potential mechanism for sensitization to liver damage. Hepatology 2000; 31: 633-640
50. +T cells but induces type 1 T cells in the liver by induction of IL-12 and IL-18 production from Kupffer cells. J Immunol 1997; 159: 97-106
51. Cohen P, Zhao C, Cai X et al. Selective delection of leptin receptor in neurons leads to obesity. J Clin Invest 2001; 108: 1113-1121
52. Minagawa M, Oya H, Yamamoto S et al. Intensive expansion of natural killer T cells in the early phase of hepatocyte regeneration after partial hepatectomy in mice and its association with sympathetic nerve activation. Hepatology 2000; 31: 907-915
53. Aggarwal B. Tumor necrosis factors receptor associated signalling molecules and their role in activation of apoptosis, JNK and NK-KB. Ann Rheum Dis 2000; 59 (suppl. 1): 16-116
54. Li Z, Yang S, Lin H et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve non-alcoholic fatty liver disease. Hepatology 2003; 37: 343-350
55. Ruan H, Lodish HF. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev 2003; 14: 447-455
56. Li Z, Oben JA, Yang S et al. Norepinephrine regulates hepatic innate immune system in leptin-deficient mice with nonalcoholic steatohepatitis. Hepatology 2004; 40: 434-441
57. Bruun JM, Lihn AS, Verdich C et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 2003; 285: E527-33
58. Yamauchi T, Kamon J, Minokoshi Y et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288-1295
59. Xu A, Wang Y, Keshaw H et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91-100
60. Yamauchi T, Kamon J, Waki H et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-946
61. Pajvani UB, Du X, Combs TP et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 2003; 278: 9073-9085
62. Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003; 148: 293-300
63. Esposito K, Pontillo A, Di Palo C et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003; 289: 1799-1804
64. Gabriely I, Barzilai N. Surgical removal of visceral adipose tissue: effects on insulin action. Curr Diab Rep 2003; 3: 201-206
65. Solomon SS, Mishra SK, Cwik C et al. Pioglitazone and metformin reverse insulin resistance induced by tumor necrosis factor-alpha in liver cells. Horm Metab Res 1997; 29: 379-382
66. Haukeland JW, Damas JK, Konopski Z et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCCL2. J Hepatol 2006; 44: 1167-1174
67. Senn JJ, Klover PJ, Novak IA et al. Interleukin 6 induces cellular insulin resistance in hepatocytes. Diabetes 2002; 51: 3391-3399
68. Robinson SC, Scott KA, Balkwill FR. Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNF - alpha. Eur J Immunol 2002; 32: 404-412
69. Dahlman I, Kaaman M, Olsson T et al. A unique role of monocyte chemoattractant protein among chemokines in adipose tissue of obese subjects. J Clin Endocrinol Metab 2005; 90: 5834-5840
70. Weisberg SP, Hunter D, Huber R et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 2006; 116: 115-124
71. Saxena NK, Ikeda K, Rockey DC et al. Leptin in hepatic fibrosis: evidence for inceased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 2002; 35: 762-771
72. Ikejima K, Takei Y, Honda H et al. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 2002; 122: 1399-1410
73. de Lalla C, Galli G, Aldrighetti L. Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis. J Immunol 2004; 173: 1417-1425
74. Zhu Z, Homer RJ, Wang Z. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999; 103: 779-788
75. Yokohama S, Yoneda M, Haneda M. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004; 40: 1222-1225
76. Potter JJ, Mezey E. Leptin deficiency reduces but does not eliminate the development of hepatic fibrosis in mice infected with Schistosoma mansoni. Liver 2002; 22: 173-177
77. Leclercq IA, Farrell GC, Schriemer R et al. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 2002; 37: 206-213
78. Commins SP, Marsh DJ, Thomas SA et al. Norepinephrine is required for leptin effects on gene expression in brown and white adipose tissue. Endocrinology 1999; 140: 4772-4778
79. Oben JA, Roskams T, Yang S et al. Norepinephrine induces hepatic fibrogenesis in leptin deficient ob/ob mice. Biochem Biophys Res Commun 2003; 308: 284-292